IL124881A0 - Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer - Google Patents

Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Info

Publication number
IL124881A0
IL124881A0 IL12488197A IL12488197A IL124881A0 IL 124881 A0 IL124881 A0 IL 124881A0 IL 12488197 A IL12488197 A IL 12488197A IL 12488197 A IL12488197 A IL 12488197A IL 124881 A0 IL124881 A0 IL 124881A0
Authority
IL
Israel
Prior art keywords
centchroman
enantiomer
prophylaxis
manufacture
treatment
Prior art date
Application number
IL12488197A
Other languages
English (en)
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of IL124881A0 publication Critical patent/IL124881A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12488197A 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer IL124881A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1000096P 1996-01-11 1996-01-11
DK77696 1996-07-11
PCT/DK1997/000007 WO1997025034A1 (en) 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Publications (1)

Publication Number Publication Date
IL124881A0 true IL124881A0 (en) 1999-01-26

Family

ID=26064631

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12488197A IL124881A0 (en) 1996-01-11 1997-01-09 Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer

Country Status (12)

Country Link
EP (1) EP0873119A1 (xx)
JP (1) JP2001500101A (xx)
KR (1) KR19990077157A (xx)
AU (1) AU1367197A (xx)
BR (1) BR9706966A (xx)
CA (1) CA2241462A1 (xx)
CZ (1) CZ217198A3 (xx)
HU (1) HUP9901633A3 (xx)
IL (1) IL124881A0 (xx)
NO (1) NO983177L (xx)
PL (1) PL328135A1 (xx)
WO (1) WO1997025034A1 (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1143899A (en) * 1997-11-10 1999-05-31 Novo Nordisk A/S Transdermal delivery of 3,4-diarylchromans
US7005428B1 (en) 1998-06-11 2006-02-28 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
US6465445B1 (en) 1998-06-11 2002-10-15 Endorecherche, Inc. Medical uses of a selective estrogen receptor modulator in combination with sex steroid precursors
AU2004200099B2 (en) * 1998-06-11 2006-11-02 Endorecherche, Inc. Medical Uses of A Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
AU2011253842B2 (en) * 1998-06-11 2014-08-14 Endorecherche Inc. Medical Uses of a Selective Estrogen Receptor Modulator in Combination with Sex Steroid Precursors
ES2553101T3 (es) 2004-10-20 2015-12-04 Endorecherche Inc. Precursor de esteroides sexuales en combinación con un modulador selectivo del receptor de estrógenos para la prevención y tratamiento de atrofia vaginal en mujeres postmenopáusicas
US8268806B2 (en) 2007-08-10 2012-09-18 Endorecherche, Inc. Pharmaceutical compositions
CN101896174B (zh) 2007-10-16 2012-10-31 利普生物药剂公司 用于治疗代谢综合征的珠氯米芬
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
KR20140089402A (ko) 2010-06-16 2014-07-14 앙도르쉐르슈 인코포레이티드 에스트로겐-관련 질병의 치료 또는 예방 방법
CN104244953A (zh) 2012-02-29 2014-12-24 利普生物药剂公司 用于治疗雄激素缺乏的联合治疗
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
US11633382B2 (en) 2015-11-10 2023-04-25 Paracrine Therapeutics Ab Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447622A (en) * 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof

Also Published As

Publication number Publication date
CZ217198A3 (cs) 1998-11-11
JP2001500101A (ja) 2001-01-09
EP0873119A1 (en) 1998-10-28
BR9706966A (pt) 1999-05-04
AU1367197A (en) 1997-08-01
HUP9901633A2 (hu) 1999-10-28
PL328135A1 (en) 1999-01-18
WO1997025034A1 (en) 1997-07-17
CA2241462A1 (en) 1997-07-17
KR19990077157A (ko) 1999-10-25
NO983177L (no) 1998-07-10
HUP9901633A3 (en) 2000-02-28

Similar Documents

Publication Publication Date Title
IL112969A0 (en) Pharmaceutical composition comprising t-cell actiVator for the treatment of cancer
ZA957483B (en) Compounds and methods for the treatment of cancer
ZA96740B (en) Skin treatment composition
EP0942742A4 (en) THERAPEUTIC COMPOSITIONS FOR CANCER TREATMENT
AU1980995A (en) Methods and compositions for treatment of breast cancer
ZA953256B (en) Skin treatment composition
HUP9903166A3 (en) Medicinal compositions for the prophylaxis or treatment of arteriosclerosis
IL132287A0 (en) Compositions and methods for the treatment and diagnosis of breast cancer
IL124881A0 (en) Use of the l-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
AU5005197A (en) Prophylaxis of breast cancer
IL121329A0 (en) A pharmaceutical composition for the treatment of cancer
ZA952121B (en) Skin treatment composition
IL101317A0 (en) New compounds for use in the treatment of cancer
EP0918788A4 (en) BRCA1 COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING BREAST CANCER
ZA97215B (en) Use of the i-enantiomer of centchroman for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of breast cancer
EP0755262A4 (en) PNEUMOPATHY TREATMENT COMPOSITION
ZA952120B (en) Skin treatment composition
GB2312375B (en) Agents for treatment of cancer
HU9700079D0 (en) Topical compositions for the treatment of skin disease
ZA979720B (en) Prophylaxis of breast cancer
EP0460690A3 (en) Use of phenolsulfophthaline derivatives for the treatment of osteoporosis
EP0810866A4 (en) USE IN THE TREATMENT OF CANCERS OF ORGANOMETALLIC COMPOUNDS OF ACID-SENSITIVE TRANSITION METALS
IL123422A0 (en) Use of 7alpha-methyl-17alpha-ethynyl-estrane derivatives for the manufacture of a medicament for the prophylaxis or the treatment of atherosclerosis
IL115200A0 (en) Pharmaceutical compositions for the treatment of cancer
IL124488A0 (en) A preparation for the treatment of psoriasis